the results of the trial- which shows reduced rates of cancer recurrence after therapy, by 44%, and was 77% effective after 18 months, in combination with Merck's Keytruda, versus Keytruda alone.
But, on the flip side, "bears point to baseline imbalances between study arms, a small trial with a liberal threshold for statistical signal, and evolving standard-of-care in melanoma towards immunotherapy in the neo-adjuvant setting,"
$ the battle continues$
Market Data 
Markets 
AI
